Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)

November 13, 2026 updated by: Viking Therapeutics, Inc.

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants With Type 2 Diabetes Mellitus Who Are Obese, or Overweight

This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This is a Phase 3, multicenter, 68-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 oral formulation in adults with Type 2 Diabetes Mellitus (T2DM) who are obese or overweight.

Study Type

Interventional

Enrollment (Estimated)

560

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Arizona
      • Tucson, Arizona, United States, 85741
        • Recruiting
        • Viking Clinical Site #2020
        • Contact:
          • Phone Number: 520-333-4515
    • California
      • Lake Forest, California, United States, 92630
        • Recruiting
        • Viking Clinical Site #2015
        • Contact:
          • Phone Number: 714-550-9990
    • Florida
      • Ocoee, Florida, United States, 34761
        • Recruiting
        • Viking Clinical Site #2059
        • Contact:
          • Phone Number: 407-654-2724
    • Georgia
      • Atlanta, Georgia, United States, 30329
        • Recruiting
        • Viking Clinical Site #2013
        • Contact:
          • Phone Number: 404-920-6201
    • Indiana
      • Evansville, Indiana, United States, 47714
        • Recruiting
        • Viking Clinical Site #2001
        • Contact:
          • Phone Number: 812-477-2760
      • Indianapolis, Indiana, United States, 46202
        • Recruiting
        • Viking Clinical Site #2046
        • Contact:
          • Phone Number: 504-336-2667
      • Valparaiso, Indiana, United States, 46383
        • Recruiting
        • Viking Clinical Site #2009
        • Contact:
          • Phone Number: 219-464-8302
    • Minnesota
      • Richfield, Minnesota, United States, 55423
        • Recruiting
        • Viking Clinical Site #2004
        • Contact:
          • Phone Number: 952-922-7000
    • Mississippi
      • Jackson, Mississippi, United States, 39206
        • Recruiting
        • Viking Clinical Site #2029
        • Contact:
          • Phone Number: 770-330-4157
    • Missouri
      • Springfield, Missouri, United States, 65807
        • Recruiting
        • Viking Clinical Site #2028
        • Contact:
          • Phone Number: 504-338-0917
    • New Mexico
      • Albuquerque, New Mexico, United States, 87107
        • Recruiting
        • Viking Clinical Site #2052
        • Contact:
          • Phone Number: 505-243-1627
    • New York
      • Binghamton, New York, United States, 13905
        • Recruiting
        • Viking Clinical Site #2039
        • Contact:
          • Phone Number: 607-800-5777
    • Oregon
      • Medford, Oregon, United States, 97504
        • Recruiting
        • Viking Clinical Site #2023
        • Contact:
          • Phone Number: 541-858-1018
    • Rhode Island
      • East Greenwich, Rhode Island, United States, 02818
        • Recruiting
        • Viking Clinical Site #2002
        • Contact:
          • Phone Number: 401-739-9350
    • South Carolina
      • Charleston, South Carolina, United States, 29407
        • Recruiting
        • Viking Clinical Site #2044
        • Contact:
          • Phone Number: 843-432-2477
    • Tennessee
      • Hendersonville, Tennessee, United States, 37075
        • Recruiting
        • Viking Clinical Site #2030
        • Contact:
          • Phone Number: 504-339-0917
    • Texas
      • Abilene, Texas, United States, 79606
        • Recruiting
        • Viking Clinical Site #2031
        • Contact:
          • Phone Number: 325-400-1150
    • Washington
      • Seattle, Washington, United States, 98105
        • Recruiting
        • Viking Clinical Site #2011
        • Contact:
          • Phone Number: 206-536-3030
      • Spokane, Washington, United States, 99218
        • Recruiting
        • Viking Clinical Site #2042
        • Contact:
          • Phone Number: 509-505-6227

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Age ≥18 years of age at the time of signing the informed consent.
  2. Body mass index (BMI) ≥ 27 kg/m2
  3. Have Type 2 Diabetes Mellitus according to the American Diabetes Association (See Section 12.5), with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Participants with HbA1c between 6.5%-6.9% or 11.0%-11.5% are allowed to have a single HbA1c retesting to confirm eligibility. Type 2 Diabetes Mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists.

Exclusion Criteria:

  1. History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation

  2. Self-reported body weight change of 5% or more within 3 months of screening

  3. Have a prior or planned surgical treatment for obesity such as a gastric sleeve, lap band or any form of bariatric surgery (except for liposuction or abdominoplasty if performed >1 year prior to screening)

  4. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)

  5. Have Type 1 Diabetes Mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 Diabetes Mellitus (T2DM)

  6. Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening

    • Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG < 54 mg/dL.

  7. Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values > 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization

  8. Have non-proliferative diabetic retinopathy that requires acute treatment OR diabetic macular edema OR proliferative diabetic retinopathy identified during a dilated fundoscopy examination performed within 3 months of screening. Please see Section 7.6.

  9. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)

  10. History of acute or chronic pancreatitis

  11. Thyroid disease that is not controlled (Thyroid stimulating hormone (TSH) outside normal range by central lab at screening; one repetition during screening is allowed). Participants with previous history of partial/total thyroidectomy or hypothyroidism may be included, provided their hormone replacement dose has been stable for 3 months prior to screening.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo Assignment

Placebo comparator orally once daily

Placebo comparator administered orally once daily

Experimental: Active Assignment (Dose 1)

VK2735 Dose level 1 orally once daily

VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily

Experimental: Active Assignment (Dose 2)

VK2735 Dose level 2 orally once daily

VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily

Experimental: Active Assignment (Dose 3)

VK2735 Dose level 3 orally once daily

VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily
Time Frame: 68 weeks

To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68

68 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

October 1, 2028

Study Completion (Estimated)

December 1, 2028

Study Registration Dates

First Submitted

October 5, 2026

First Submitted That Met QC Criteria

October 5, 2026

First Posted (Actual)

October 9, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • VK2735-305

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.